Sandra Guallar-Garrido

Jan 15, 2024 | nature.com | Cristina Simó |Ana C. Hortelao |Valerio Di Carlo |Sandra Guallar-Garrido |Pedro Ramos-Cabrer |Vanessa Gómez-Vallejo | +6 more

AbstractBladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored.